Cytosorbents Corporation
Moat Score — Cytosorbents Corporation
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | A decade-plus patent and trademark estate covering the core polymer-bead adsorption technology, two FDA Breakthrough Device Designations for DrugSorb-ATR, and a real-world evidence base of over 300,000 cumulative treatments across 70+ countries represent genuine, hard-to-replicate intangible assets for a company of this size. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | CytoSorbents remains unprofitable with a $14.7 million operating loss on $37.1 million of revenue in FY2025, and lacks the manufacturing scale of larger diversified medical device rivals like Baxter or Toray, so it holds no discernible cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | 71% gross margin reflects device economics typical of single-use medical disposables, but adoption and pricing remain highly dependent on country-specific reimbursement codes (e.g., Germany's OPS 8-821.30), and the core CytoSorb product still lacks full FDA approval in the largest global market, limiting true pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | CytoSorb and DrugSorb-ATR are single-use clinical devices used per patient per treatment; there is no network effect where the product becomes more valuable as more hospitals or patients use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Cartridges are used alongside existing CRRT/ECMO/bypass equipment already installed in hospitals, and competing adsorption filters (e.g., Baxter's Oxiris) can be substituted on the same platforms relatively easily, so clinical switching costs are modest rather than structural. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The extracorporeal blood-purification niche is small enough that it has not attracted a large number of pure-play entrants, but CytoSorbents itself is dwarfed by diversified incumbents like Baxter, Toray, and Jafron that can bundle adsorption products with their own installed CRRT platforms, limiting any scale-based protection. |